Efficacy and safety of iclepertin (BI 425809) in patients with schizophrenia: CONNEX, a Phase III randomised controlled trial programme
Introduction Cognitive impairment (CI) is a major determinant of poor functional outcome in schizophrenia and there are currently no available pharmacotherapies. Deficits in glutamatergic signalling play a key role in the neuropathology of cognitive symptoms. Iclepertin (BI 425809), an inhibitor of...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2023-03-01
|
Series: | European Psychiatry |
Online Access: | https://www.cambridge.org/core/product/identifier/S0924933823013251/type/journal_article |